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Abstract
Background: Progression in disability as measured by increase in the Expanded Disability Status Scale (EDSS) is 
commonly used as outcome variable in clinical trials concerning multiple sclerosis (MS). In this study, we addressed the 
question, whether there is a linear relationship between disability status and health related quality of life (HRQOL) in 
MS.
Methods: 7305 MS patients were sent a questionnaire containing a German version of the "Multiple Sclerosis Quality 
of Life (MSQOL)-54" and an assessment of self-reported disability status analogous to the EDSS. 3157 patients 
participated in the study. Patients were allocated to three groups according to disability status.
Results: Regarding the physical health composite and the mental health composite as well as most MSQOL-54 
subscales, the differences between EDSS 4.5-6.5 and EDSS >= 7 were clearly smaller than the differences between EDSS 
<= 4 and EDSS 4.5-6.5.
Conclusion: These results indicate a non-linear relationship between disability status and HRQOL in MS. The EDSS 
does not seem to be interval scaled as is commonly assumed. Consequently, absolute increase in EDSS does not seem 
to be a suitable outcome variable in MS studies.
Introduction
Progression in disability as measured by increase in the
Expanded Disability Status Scale (EDSS) is a frequently
used outcome variable in clinical trials concerning multi-
ple sclerosis (MS) [1-5].
However, EDSS represents only a part of health related
quality of life (HRQOL) in MS. HRQOL comprises sev-
eral domains in addition to physical impairments like
social functioning and psychological well-being [6,7].
There is a growing interest in HRQOL in MS patients and
several studies have been performed addressing this topic
[8-18]. MS-patients have reduced quality of life within
the different aspects of HRQOL in comparison to the
general population [17,19-23]. There appears to be a rela-
tionship between EDSS and HRQOL, although some
studies find a relationship only with physical functioning,
rather with psychological functioning or psychological
well-being [9,11,22,24-29].
Results from several studies suggest a non-linear rela-
tionship between EDSS and HRQOL in MS. In a study by
Vickrey et al., the difference between patients who
walked with an aid and wheelchair-bound patients was
smaller than the difference between patients walking
without help and patients being dependent on a walking
aid in most HRQOL domains [30]. Similarly, Patti et al.
reported no significant difference between a patient
group with high EDSS scores and a group with moderate
EDSS scores in nearly all domains, whereas groups with
low and moderate EDSS scores differed significantly in all
domains [26].
In this study, comprising a large sample with a broad
spectrum of patients, we addressed the question, whether
there is a linear relationship between disability status and
HRQOL in patients with MS. We therefore explored the
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difference regarding HRQOL between patients with dif-
fering ambulation status. Three groups of patients were
compared for this purpose: patients who are confined to a
wheelchair, patients who are impaired in ambulation
without being wheelchair-bound, and patients with
largely unimpaired ambulation.
Materials and methods
Sample
Data were collected using a postal survey of all 7305 MS-
patients registered as patient members of the German
MS Society in North Rhine-Westphalia. 3157 patients
volunteered to participate, giving a response rate of
43.2%.
Questionnaires
The survey included a German version of the Multiple
Sclerosis Quality of Life (MSQOL)-54 Questionnaire and
a structured demographic and clinical questionnaire [30].
The MSQOL-54 comprises questions from the Short
Form 36-Item Health Survey as a generic measure of
quality of life, and 18 additional MS specific items
[7,31,32]. The MSQOL-54 has high test-retest reliability
and high internal consistency. Evidence supports its con-
tent and construct validity [30,33]. Persian, Finnish,
Greek, and Serbian versions have recently been validated
[34-37], as well as Italian, French and Turkish versions
have been validated a few years ago [38-40]. There is evi-
dence that also the German version used here has satis-
factory reliability and validity [41]. The 54 items of the
MSQOL-54 are distributed into 12 multi-item scales and
two single-item scales [30]. Due to technical and psycho-
metric reasons the scale "vitality" was reduced by one
item. For statistical analysis scale scores were created by
averaging items within scales and transforming average
scores linearly to 0-100 possible scores, with higher val-
ues indicating better quality of life. Missing values were
replaced by the mean of the remaining items constituting
a scale, unless there were missing more than 50% of items
in the concerning scale. In addition physical and mental
health composite scores were determined as weighted
sums of selected scale scores as described by Vickrey et
al. [30]. Composite scores, too, had a range of 0-100.
Self-report questions about ambulation status were
developed which were analogous to information from the
Expanded Disability Status Scale (EDSS) [42]. The EDSS
has a possible range from 0, indicating no disability and
normal neurological examination, to 10, referring to
death due to MS. For this analysis, patients were allocated
to one of three groups based on their responses to the
self-report questions. Group 1 included patients who
were able to walk at least 1000 meters without help (cor-
responding to an EDSS score <= 4.0). Group 2 comprised
people able to walk at least 100 metres with or without
aid (EDSS score between 4.5 and 6.5). Patients in group 3
were largely confined to a wheelchair (EDSS >= 7.0).
Duration of disease was expressed as years of time since
diagnosis instead of time since onset of disease.
Procedures
In July and August 2004, patients were sent the question-
naires and a cover letter which asked for participation,
explained the importance of participation and clearly
stated that all information would be treated in strict con-
fidence. A pre-stamped and pre-addressed envelope was
included. Patients were invited to call if they required fur-
ther information.
Statistical Analysis
Univariate analyses of covariance (general linear model)
were computed to evaluate differences regarding
MSQOL subscales and composite scores between sub-
groups with different ambulation status. Gender was
included as an additional factor while age and duration of
disease were considered as covariates.
Due to multiple comparisons the results were consid-
ered statistically significant only if p values were <.01.
Statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS), version 15.
The research protocol of the study was reviewed and
approved by the Committee of Research Ethics at the
Medical Faculty of the Technical University of Dresden. It
was carried out in accordance with the Declaration of
Helsinki. All subjects received written information on the
study and gave written informed consent prior to partici-
pation.
Results
Proportions of missing results varied between 3.8% and
7.8% for the mentioned demographic and disease-related
variables and between 1.9% (cognitive function) and
16.5% (sexual function) for MSQOL-54 subscales after
replacing missing values as described above.
Demographic and disease related characteristics
71.7% of the 3045 respondents were women (table 1). The
mean age of the respondents was 48.2 years. Mean dura-
tion of disease was 13.2 years. 1429 (47.6%) patients were
able to walk at least 1000 metres without help (group 1),
633 (21.1%) patients could walk at least 100 metres
(group 2), and 938 (31.3%) patients were largely confined
to a wheelchair (group 3). The three groups differed
clearly from each other in terms of gender, age, and dura-
tion of disease, i.e., the worse the ambulation status, the
higher the proportion of men and the higher age and dis-
ease duration.Twork et al. Health and Quality of Life Outcomes 2010, 8:55
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Quality of Life
The scores of both MSQOL-54 composites and most
subscales were distributed over a broad spectrum. Only
in the role limitations (physical) scale and the role limita-
tions (emotional) scale, there were so called floor and
ceiling effects (i.e., many very low or very high scores).
As shown in figure 1, the physical health composite as
well as the mental health composite score of the
MSQOL-54 decreased significantly as a function of
ambulation status (p = .000). The differences between
groups 1 and 2 were clearly larger than those between
groups 2 and 3. With regard to the physical health com-
posite, group 1 and group 2 differed significantly from
each other (p = .000) as well as groups 1 and 3 (p = .000)
and groups 2 and 3 (p = .000). The mean scores for the
mental health composite differed significantly only
between group 1 and group 2 (p = .000) as well as
between groups 1 and 3 (p = .000). The difference
between groups 2 and 3 was not significant (p = .134).
The mean subscale scores of the MSQOL-54 are pre-
sented in table 2. The mean scores on all scales decreased
with worsening ambulation status. The difference
between groups 2 and 3 was smaller than the one
between groups 1 and 2 on all of these subscales except
for cognitive function. Groups 1 and 2 differed signifi-
cantly with regard to all subscales (all p < .010) but cogni-
tive function (p = 1.000) and role limitations (emotional)
(p = .017). Between group 2 and group 3, significant dif-
ferences were found only in physical function, social
function, overall quality of life and sexual function (all p <
.010). Regarding the other scales groups 2 and 3 did not
differ significantly (p > .016 for pain and p > .055 for the
remaining scales, respectively).
Men and women differed significantly in role limita-
tions (physical), pain and sexual function (all p < .010),
with men having the higher score in pain and the lower
scores in role limitations (physical) as well as sexual func-
tion (table 2). Gender effects were not significant on the
other subscales and on the composite scores (p > .014 for
health perceptions and cognitive function, and p > .110
for the remaining scales, respectively).
Regarding sexual function, there was a significant inter-
action effect between gender and ambulation status sub-
group (p = .000). As can be seen in figure 2, in men the
difference between groups 1 and 2 (mean 67.1 and 48.5,
respectively) was clearly larger than the difference
between group 2 and 3 (42.1), whereas in women groups
1 and 2 differed only slightly (69.1 and 66.8, respectively)
in comparison to group 2 and group 3 (59.0). Regarding
the other scales, no significant interaction effects were
found (p = .028 for health distress and p > .092 for the
remaining scales, respectively).
Discussion
The goal of the study was to explore the nature of the
relationship between disability as measured by EDSS and
HRQOL in MS. Therefore, we assessed the differences
between patient groups with differing disability status
regarding their MSQOL-54 scale scores.
The physical and the mental health composite of the
MSQOL-54 as well as all subscale scores but cognitive
function decreased with worsening disability status.
However , while patients with an estimated EDSS score
between 4.5 and 6.5 differed markedly from patients with
a lower EDSS (0 - 4.0), the difference between the two
groups of patients with higher EDSS scores (4.5 - 6.5 and
7.0 - 10.0, respectively) was smaller on all of these scales,
Figure 1 Mean MSQOL-54 composite scores (adjusted for effects 
of age and disease duration; with standard deviations) of the 
three ambulation status subgroups.
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Table 1: Demographic and disease characteristics of the total sample and of the three ambulation status subgroups
Ambulation status
Total sample Group 1 Group 2 Group 3
n 3157 1429 633 938
% Women 71.7 77.0 70.5 63.6
Age (years; m +/- SD) 48.2 +/- 11.8 42.9 +/- 9.8 50.4 +/- 10.5 54.7 +/- 11.5
Years since diagnosis
(m +/- SD)
13.2 +/- 9.4 9.3 +/- 7.1 13.8 +/- 9.0 18.6 +/- 9.8Twork et al. Health and Quality of Life Outcomes 2010, 8:55
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not even being significant on the mental health compos-
ite and most of the subscales. Hence, the results suggest,
that whereas impaired ambulation (without confinement
to a wheelchair) is accompanied by striking deteriora-
tions in HRQOL, being bound to a wheelchair does not
lead to decisive additional decreases in most HRQOL
domains.
The results are in agreement with those of previous
studies. In a study by Patti et al. patients with EDSS scores
lower 3.0 scored significantly better than two groups with
higher EDSS scores in all dimensions of the SF-36 [26]. In
the contrary, there was less difference between these lat-
ter two groups. Patients with EDSS scores of 3.0 to 6.0
had markedly higher scores than patients with EDSS
scores over 6.0 only for physical functioning. Vickrey et
al., too, found larger differences between patients who
could walk without help and patients who required assis-
tance to ambulate than between this latter group and
p a t i e n t s  w h o  w e r e  c o n f i n e d  t o  a  w h e e l c h a i r  o n  m o s t
MSQOL-54 scales [30].
Interestingly, in our study this pattern was found for
sexual function only in men. In women the difference
between groups 1 and 2 was smaller than in men, whereas
the difference between groups 2 and 3 did not differ from
the one found in men. Hence, the relationship between
ambulation status and sexual dysfunction seems to be dif-
ferent in men and in women.
Consistently with the results of other studies, cognitive
function scores did not vary significantly between groups
[43,44]. Hence, cognitive function and ambulation appear
to be independent.
Gender effects were only observed in three subscales.
Likewise, other studies reported gender effects in only
few or none of the HRQOL domains, respectively
[17,21,22,26,44-46].
Table 2: Mean scores on the 12 MSQOL-54 subscales and the two composite scores for the total sample, by gender and by 
ambulation status (the latter two adjusted for effects of age and disease duration)
Gender Level of ambulation
Total Sample Men Women Group 1 Group 2 Group 3
Physical function 44.0 +/- 33.9 37.7 +/- 22.1 37.1 +/- 23.2 67.9 +/- 26.1b,c 28.9 +/- 23.4b,d 15.4 +/- 23.3d,c
Role (physical) 35.8 +/- 40.6 35.0 +/- 37.9 a 30.0 +/- 40.2 a 51.2 +/- 44.9b,c 25.5 +/- 40.3b 20.9 +/- 40.1c
Role (emotional) 58.2 +/- 44.5 58.8 +/- 45.4 57.0 +/- 48.6 64.6 +/- 53.6c 57.1 +/- 48.0 52.1 +/- 47.5c
Pain 65.4 +/- 29.2 69.9 +/- 28.4 a 62.5 +/- 29.6 a 72.2 +/- 33.7b,c 65.5 +/- 30.0b 60.8 +/- 30.4c
Emotional well-being 61.3 +/- 20.1 62.1 +/- 21.2 60.6 +/- 22.0 64.0 +/- 25.0b,c 60.2 +/- 22.4b 59.9 +/- 22.5c
Energy 39.7 +/- 19.8 39.7 +/- 20.3 38.3 +/- 21.1 44.9 +/- 24.1b,c 37.0 +/- 21.6b 35.1 +/- 21.7c
Health perceptions 43.9 +/- 18.9 41.4 +/- 19.0 43.2 +/- 19.8 48.9 +/- 22.5b,c 40.2 +/- 20.1b 37.9 +/- 20.3c
Social function 65.1 +/- 24.9 63.0 +/- 23.5 63.7 +/- 24.4 75.2 +/- 27.8b,c 61.0 +/- 24.7b,d 53.8 +/- 25.1d,c
Cognitive function 68.4 +/- 22.9 66.5 +/- 24.0 69.1 +/- 24.9 69.0 +/- 28.4 68.2 +/- 25.4 66.3 +/- 25.7
Health distress 62.8 +/- 21.9 61.7 +/- 22.2 61.7 +/- 23.1 69.6 +/- 26.3b,c 59.3 +/- 23.5b 56.3 +/- 23.7c
Overall quality of life 58.0 +/- 24.5 55.0 +/- 23.0 56.2 +/- 24.0 66.8 +/- 27.2b,c 53.9 +/- 24.3b,d 46.1 +/- 24.6d,c
Sexual function 61.2 +/- 33.6 52.6 +/- 31.6 a 65.0 +/- 33.2 a 68.1 +/- 35.9b,c 57.7 +/- 32.3b,d 50.6 +/- 32.6d,c
physical health composite 52.7 +/- 19.7 49.6 +/- 16.9 48.9 +/- 18.3 62.5 +/- 19.1b,c 45.5 +/- 17.2b,d 39.8 +/- 17.2d,c
mental health composite 62.0 +/- 21.3 61.1 +/- 22.0 60.6 +/- 23.6 66.3 +/- 25.8b,c 59.6 +/- 23.1b 56.7 +/- 22.9c
ap < .01 men vs. women (ANCOVA)
bp < .01 group 1 vs. group 2 (ANCOVA)
cp < .01 group 1 vs. group 3 (ANCOVA)
dp < .01 group 2 vs. group 3 (ANCOVA)
Figure 2 Mean sexual function scores (adjusted for effects of age 
and disease duration; with standard deviations) of the three am-
bulation status subgroups for men and for women.
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The data obtained in this study clearly suggest a non-
linear relationship between HRQOL and disability status
as measured by EDSS. This is the case for physical as well
as for mental quality of life. The EDSS does not seem to
b e  i n t e r v a l  s c a l e d  a s  i s  c o m m o n l y  a s s u m e d .  T h e  s t e p
from largely unimpaired ambulation to impaired ambula-
tion status and the next step towards restriction to a
wheelchair are not equal in distance. Therefore, absolute
increase in EDSS, e.g. one point per year, is not suited for
outcome variable in clinical trials in which the effective-
ness of MS immunotherapy is examined. This outcome
measure has been used in a number of decisive clinical
trials [1-3]. Following the findings of the present study,
this is inappropriate, unless the investigators take care of
strictly homogenous samples with low variations in base-
line disability status. As an alternative, a proportional
decrease in disability as assessed relative to the baseline
EDSS scores should be used as an outcome measure. In
general, MS-specific measure of quality of life should be
used for detecting treatment effects [47]. Future research
may address the precise definition of such a measure.
Assessing EDSS scores based on self-ratings of ambula-
tion status can be seen as one limitation of this study. Yet,
the EDSS itself relies heavily on ambulation. Besides, a
number of authors emphasize that a self-rating of disabil-
ity status can be seen as a good substitute for neurological
assessment if this is not available [25,26,48]. The advan-
tage of this proceeding in the present study was that it
was possible to examine a very large sample this way.
The German MS Society is divided into parts similar to
the federal states of Germany and supports around
50,000 MS patients. The patients from the North Rhine-
Westphalian section represent the largest proportion
compared to the other German sections. The question is
to which extent these patients are representative for the
whole German MS community. On the other hand a pos-
sible selection bias has to be discussed. Thus, members of
the MS Society could form a special subgroup (maybe
older, with longer disease duration) and patients working
on the questionnaire could be especially motivated. The
response rate obtained in this study was not as high as
was hoped for, but the sample nonetheless is relatively
large and covers a brought spectrum of patients. With
regard to age, gender and duration of disease the distribu-
tion given in this sample is in line with the one found in
other studies of MS patients [9,22,45,46,49].
Conclusion
In conclusion, the results of the present study indicate a
nonlinear relationship between disability status and
HRQOL. They therefore contradict the assumption that
the EDSS is interval scaled. Consequently, absolute
increase in EDSS does not seem to be a suitable outcome
variable in MS studies.
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